TY - JOUR AU - Tariq, N. U. AU - McNamara, M. G. AU - Valle, J. W. PY - 2019 DA - 2019// TI - Biliary tract cancers: current knowledge, clinical candidates and future challenges JO - Cancer Manag Res VL - 11 UR - https://doi.org/10.2147/CMAR.S157092 DO - 10.2147/CMAR.S157092 ID - Tariq2019 ER - TY - JOUR AU - Marcano-Bonilla, L. AU - Mohamed, E. A. AU - Mounajjed, T. AU - Roberts, L. R. PY - 2016 DA - 2016// TI - Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations JO - Chin Clin Oncol VL - 5 UR - https://doi.org/10.21037/cco.2016.10.09 DO - 10.21037/cco.2016.10.09 ID - Marcano-Bonilla2016 ER - TY - JOUR AU - Dyke, A. L. AU - Shiels, M. S. AU - Jones, G. S. AU - Pfeiffer, R. M. AU - Petrick, J. L. AU - Beebe-Dimmer, J. L. PY - 2019 DA - 2019// TI - Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013 JO - Cancer. VL - 125 UR - https://doi.org/10.1002/cncr.31942 DO - 10.1002/cncr.31942 ID - Dyke2019 ER - TY - STD TI - National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Hepatobiliary Cancers. Version 4.2019. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed 3 Jan 2020. UR - https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf ID - ref4 ER - TY - JOUR PY - 2018 DA - 2018// TI - Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 JO - Lancet VL - 392 UR - https://doi.org/10.1016/S0140-6736(18)32203-7 DO - 10.1016/S0140-6736(18)32203-7 ID - ref5 ER - TY - JOUR AU - Park, J. O. AU - Oh, D. Y. AU - Hsu, C. AU - Chen, J. S. AU - Chen, L. T. AU - Orlando, M. PY - 2015 DA - 2015// TI - Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review JO - Cancer Res Treat VL - 47 UR - https://doi.org/10.4143/crt.2014.308 DO - 10.4143/crt.2014.308 ID - Park2015 ER - TY - JOUR AU - Brandi, G. AU - Rizzo, A. AU - Dall’Olio, F. G. AU - Felicani, C. AU - Ercolani, G. AU - Cescon, M. PY - 2020 DA - 2020// TI - Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience JO - Int J Hyperth VL - 27 UR - https://doi.org/10.1080/02656736.2020.1763484 DO - 10.1080/02656736.2020.1763484 ID - Brandi2020 ER - TY - JOUR AU - Morizane, C. AU - Okusaka, T. AU - Mizusawa, J. AU - Katayama, H. AU - Ueno, M. AU - Ikeda, M. PY - 2019 DA - 2019// TI - Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz402 DO - 10.1093/annonc/mdz402 ID - Morizane2019 ER - TY - JOUR AU - Sakai, D. AU - Kanai, M. AU - Kobayashi, S. AU - Eguchi, H. AU - Baba, H. AU - Seo, S. PY - 2018 DA - 2018// TI - Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA) [abstract] JO - Ann Oncol VL - 29 ID - Sakai2018 ER - TY - JOUR AU - Yoshikawa, D. AU - Ojima, H. AU - Iwasaki, M. AU - Hiraoka, N. AU - Kosuge, T. AU - Kasai, S. PY - 2008 DA - 2008// TI - Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma JO - Br J Cancer VL - 98 UR - https://doi.org/10.1038/sj.bjc.6604129 DO - 10.1038/sj.bjc.6604129 ID - Yoshikawa2008 ER - TY - JOUR AU - Giatromanolaki, A. AU - Koukourakis, M. I. AU - Simopoulos, C. AU - Polychronidis, A. AU - Sivridis, E. PY - 2003 DA - 2003// TI - Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas JO - Eur J Surg Oncol VL - 29 UR - https://doi.org/10.1016/j.ejso.2003.09.013 DO - 10.1016/j.ejso.2003.09.013 ID - Giatromanolaki2003 ER - TY - JOUR AU - Xu, Y. F. AU - Yang, X. Q. AU - Lu, X. F. AU - Guo, S. AU - Liu, Y. AU - Iqbal, M. PY - 2014 DA - 2014// TI - Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma JO - Biochem Biophys Res Commun VL - 446 UR - https://doi.org/10.1016/j.bbrc.2014.02.050 DO - 10.1016/j.bbrc.2014.02.050 ID - Xu2014 ER - TY - JOUR AU - Boonjaraspinyo, S. AU - Boonmars, T. AU - Wu, Z. AU - Loilome, W. AU - Sithithaworn, P. AU - Nagano, I. PY - 2012 DA - 2012// TI - Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma JO - Tumour Biol VL - 33 UR - https://doi.org/10.1007/s13277-012-0438-8 DO - 10.1007/s13277-012-0438-8 ID - Boonjaraspinyo2012 ER - TY - JOUR AU - Matsui, J. AU - Yamamoto, Y. AU - Funahashi, Y. AU - Tsuruoka, A. AU - Watanabe, T. AU - Wakabayashi, T. PY - 2008 DA - 2008// TI - E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition JO - Int J Cancer VL - 122 UR - https://doi.org/10.1002/ijc.23131 DO - 10.1002/ijc.23131 ID - Matsui2008 ER - TY - JOUR AU - Okamoto, K. AU - Kodama, K. AU - Takase, K. AU - Sugi, N. H. AU - Yamamoto, Y. AU - Iwata, M. PY - 2013 DA - 2013// TI - Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models JO - Cancer Lett VL - 340 UR - https://doi.org/10.1016/j.canlet.2013.07.007 DO - 10.1016/j.canlet.2013.07.007 ID - Okamoto2013 ER - TY - JOUR AU - Yamamoto, Y. AU - Matsui, J. AU - Matsushima, T. AU - Obaishi, H. AU - Miyazaki, K. AU - Nakamura, K. PY - 2014 DA - 2014// TI - Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage JO - Vasc Cell VL - 6 UR - https://doi.org/10.1186/2045-824X-6-18 DO - 10.1186/2045-824X-6-18 ID - Yamamoto2014 ER - TY - JOUR AU - Tohyama, O. AU - Matsui, J. AU - Kodama, K. AU - Hata-Sugi, N. AU - Kimura, T. AU - Okamoto, K. PY - 2014 DA - 2014// TI - Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models JO - J Thyroid Res VL - 2014 UR - https://doi.org/10.1155/2014/638747 DO - 10.1155/2014/638747 ID - Tohyama2014 ER - TY - STD TI - Eisai Co., Ltd. Eisai and MSD Japan commence collaboration on commercialization activities for Lenvima® (lenvatinib) in Japan [press release]. Published October 22, 2018. https://www.eisai.com/news/2018/news201888.html. Accessed 3 Jan 2020. UR - https://www.eisai.com/news/2018/news201888.html ID - ref18 ER - TY - JOUR AU - Ikeda, M. AU - Sasaki, T. AU - Morizane, C. AU - Mizuno, N. AU - Nagashima, F. AU - Shimizu, S. PY - 2017 DA - 2017// TI - A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results [abstract] JO - Ann Oncol VL - 28 ID - Ikeda2017 ER - TY - JOUR AU - Nagahama, M. AU - Ozeki, T. AU - Suzuki, A. AU - Sugino, K. AU - Niioka, T. AU - Ito, K. PY - 2019 DA - 2019// TI - Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer JO - Med Oncol VL - 36 UR - https://doi.org/10.1007/s12032-019-1263-3 DO - 10.1007/s12032-019-1263-3 ID - Nagahama2019 ER - TY - JOUR AU - Fornaro, L. AU - Cereda, S. AU - Aprile, G. AU - Girolamo, S. AU - Santini, D. AU - Silvestris, N. PY - 2014 DA - 2014// TI - Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer JO - Br J Cancer VL - 110 UR - https://doi.org/10.1038/bjc.2014.190 DO - 10.1038/bjc.2014.190 ID - Fornaro2014 ER - TY - JOUR AU - Lamarca, A. AU - Palmer, D. H. AU - Wasan, H. S. AU - Ross, P. J. AU - Ma, Y. T. AU - Arora, A. PY - 2019 DA - 2019// TI - ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy [abstract] JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2019.37.15_suppl.4003 DO - 10.1200/JCO.2019.37.15_suppl.4003 ID - Lamarca2019 ER - TY - JOUR AU - Rizzo, A. AU - Ricci, A. D. AU - Tober, N. AU - Nigro, M. C. AU - Mosca, M. AU - Palloni, A. PY - 2020 DA - 2020// TI - Second-line treatment in advanced biliary tract cancer: today and tomorrow JO - Anticancer Res VL - 40 UR - https://doi.org/10.21873/anticanres.14282 DO - 10.21873/anticanres.14282 ID - Rizzo2020 ER - TY - JOUR AU - Belkouz, A. AU - Vos-Geelen, J. AU - Mathôt, R. A. A. AU - Eskens, F. A. L. M. AU - Gulik, T. M. AU - Oijen, M. G. H. PY - 2020 DA - 2020// TI - Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial JO - Br J Cancer VL - 122 UR - https://doi.org/10.1038/s41416-019-0698-9 DO - 10.1038/s41416-019-0698-9 ID - Belkouz2020 ER - TY - JOUR AU - Abou-Alfa, G. K. AU - Macarulla Mercade, T. AU - Javle, M. AU - Kelley, R. K. AU - Lubner, S. AU - Adeva, J. PY - 2019 DA - 2019// TI - ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation [abstract] JO - Ann Oncol VL - 30 ID - Abou-Alfa2019 ER - TY - JOUR AU - Luo, X. AU - Jia, W. AU - Huang, Z. AU - Li, X. AU - Xing, B. AU - Jiang, X. PY - 2017 DA - 2017// TI - Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.12825 DO - 10.18632/oncotarget.12825 ID - Luo2017 ER - TY - JOUR AU - Sun, W. AU - Patel, A. AU - Normolle, D. AU - Patel, K. AU - Ohr, J. AU - Lee, J. J. PY - 2019 DA - 2019// TI - A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma JO - Cancer. VL - 125 UR - https://doi.org/10.1002/cncr.31872 DO - 10.1002/cncr.31872 ID - Sun2019 ER - TY - JOUR AU - Yi, J. H. AU - Thongprasert, S. AU - Lee, J. AU - Doval, D. C. AU - Park, S. H. AU - Park, J. O. PY - 2012 DA - 2012// TI - A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2011.11.017 DO - 10.1016/j.ejca.2011.11.017 ID - Yi2012 ER - TY - JOUR AU - El-Khoueiry, A. B. AU - Rankin, C. J. AU - Ben-Josef, E. AU - Lenz, H. J. AU - Gold, P. J. AU - Hamilton, R. D. PY - 2012 DA - 2012// TI - SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma JO - Investig New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-011-9719-0 DO - 10.1007/s10637-011-9719-0 ID - El-Khoueiry2012 ER - TY - JOUR AU - Kato, Y. AU - Tabata, K. AU - Hori, Y. AU - Tachino, S. AU - Okamoto, K. AU - Matsui, J. PY - 2015 DA - 2015// TI - Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors [abstract] JO - Mol Cancer Ther VL - 14 ID - Kato2015 ER - TY - JOUR AU - Kato, Y. AU - Tabata, K. AU - Kimura, T. AU - Yachie-Kinoshita, A. AU - Ozawa, Y. AU - Yamada, K. PY - 2019 DA - 2019// TI - Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway JO - PLoS One VL - 14 UR - https://doi.org/10.1371/journal.pone.0212513 DO - 10.1371/journal.pone.0212513 ID - Kato2019 ER - TY - JOUR AU - Atanasov, G. AU - Hau, H. M. AU - Dietel, C. AU - Benzing, C. AU - Krenzien, F. AU - Brandl, A. PY - 2015 DA - 2015// TI - Prognostic significance of macrophage invasion in hilar cholangiocarcinoma JO - BMC Cancer VL - 15 UR - https://doi.org/10.1186/s12885-015-1795-7 DO - 10.1186/s12885-015-1795-7 ID - Atanasov2015 ER - TY - JOUR AU - Lin, J. AU - Shi, W. AU - Zhao, S. AU - Hu, J. AU - Hou, Z. AU - Yao, M. PY - 2018 DA - 2018// TI - Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): preliminary data and correlation with next-generation sequencing [abstract] JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.4_suppl.500 DO - 10.1200/JCO.2018.36.4_suppl.500 ID - Lin2018 ER - TY - JOUR AU - Schlumberger, M. AU - Tahara, M. AU - Wirth, L. J. AU - Robinson, B. AU - Brose, M. S. AU - Elisei, R. PY - 2015 DA - 2015// TI - Lenvatinib versus placebo in radioiodine-refractory thyroid cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1406470 DO - 10.1056/NEJMoa1406470 ID - Schlumberger2015 ER - TY - JOUR AU - Motzer, R. J. AU - Hutson, T. E. AU - Glen, H. AU - Michaelson, M. D. AU - Molina, A. AU - Eisen, T. PY - 2015 DA - 2015// TI - Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00290-9 DO - 10.1016/S1470-2045(15)00290-9 ID - Motzer2015 ER - TY - JOUR AU - Vergote, I. AU - Teneriello, M. AU - Powell, M. A. AU - Miller, D. S. AU - Garcia, A. A. AU - Mikheeva, O. N. PY - 2013 DA - 2013// TI - A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes [abstract] JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/jco.2013.31.15_suppl.5520 DO - 10.1200/jco.2013.31.15_suppl.5520 ID - Vergote2013 ER -